Related Experiment Video

Updated: Jun 17, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours

T Gelardi1, V Damiano, R Rosa

  • 1Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università di Napoli Federico II, via Pansini 5, Napoli 80131, Italy.

British Journal of Cancer
|January 7, 2010
PubMed
Abstract

Insights

Novel immunoconjugates, Erbicin-derived immunoagents (EDIAs), show efficacy against trastuzumab-resistant breast cancer. These agents target ErbB2-positive cells and inhibit downstream signaling, offering a new therapeutic option for resistant cases.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • ErbB2 receptor overexpression in breast cancer correlates with disease progression and poor prognosis.
  • Trastuzumab is an effective anti-ErbB2 antibody, but resistance limits its clinical utility.
  • A significant portion of breast cancer patients exhibit primary or acquired resistance to trastuzumab.

Purpose of the Study:

  • To evaluate the efficacy of novel Erbicin-derived immunoagents (EDIAs) against trastuzumab-resistant breast cancer cells.
  • To investigate the mechanism of action of EDIAs, focusing on their interaction with ErbB2 and downstream signaling pathways.
  • To assess the potential of EDIAs as an alternative therapeutic strategy for patients resistant to trastuzumab.

Main Methods:

  • Development of two novel human anti-tumour immunoconjugates by fusing anti-ErbB2 scFv (Erbicin) with human RNase or human IgG1 Fc region.
  • Testing the selective cytotoxicity of Erbicin-derived immunoagents (EDIAs) against ErbB2-positive cancer cells in vitro and in vivo.
  • Analysis of the epitope targeted by EDIAs compared to trastuzumab and their effect on the ErbB2 signaling pathway.

Main Results:

  • EDIAs demonstrate selective cytotoxicity for ErbB2-positive cancer cells in vitro and in vivo.
  • EDIAs are effective against trastuzumab-resistant breast cancer cells, targeting a different ErbB2 epitope.
  • EDIAs inhibit the downstream signaling pathway of ErbB2, unlike trastuzumab, and do not exhibit cardiotoxicity.

Conclusions:

  • EDIAs represent a promising therapeutic option for breast cancer patients with trastuzumab resistance.
  • EDIAs offer a potential alternative for patients ineligible for trastuzumab due to cardiac issues.
  • The distinct mechanism of action and epitope targeting of EDIAs suggest broad applicability in ErbB2-positive breast cancers.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...